Showing 730 – 740 of 1303 results
-
Thomas H Lee Partners and Bynder Transaction
William Blair acted as the exclusive financial advisor to Thomas H. Lee Partners in connection with its pending acquisition of Bynder, a portfolio company of Insight Partners.
-
Will Companies Hoard Labor This Time Around
In this Economics Weekly, we look at what the current labor market data is telling us and what it might mean for the path of growth, profits, and the Fed ahead.
-
Four William Blair Advisors Make Financial Planning Top 40 Regional Advisors Under 40 List
David Brown, David Dreifuss, Andrew Feichter, and Andrew Sims were named to Financial Planning magazine’s Top 40 Regional Advisors Under 40 list released on February 2.
-
Corporate Equality Index
William Blair received a perfect score of 100% on the 2021 Corporate Equality Index, a national benchmark that measures corporate policies and practices related to LGBTQ workplace equality.
-
Solange Velazquez Most Influential Women Award
Solange-Marie Velazquez, a managing director in William Blair’s technology investment banking group, was named to Mergers & Acquisitions’ 2023 Most Influential Women in Mid-Market M&A list published February 27.
-
An Update on the Housing Market
In this week’s Economics Weekly, we are once again taking a snapshot of the current housing situation, with the conclusion that a continued moderate recovery in housing is still the base-case scenario.
-
Contino Has Agreed to be Acquired by Cognizant
William Blair acted as exclusive financial advisor to Contino, majority-owned by Columbia Capital, in connection with its pending acquisition by Cognizant.
-
The Employment Situation
In this Economics Weekly we parse this week’s reports and what they are telling us about strength in the labor market and the economy more broadly.
-
And Now for the Inventory Correction
In this Economics Weekly, we examine the current inventory situation—with supply chains now clearing but demand slowing, companies are getting a better sense of stock levels and of how much is too much.
-
Updating FDA Approval Analysis for 2024 Data
Discover the latest insights in pharmaceutical outsourcing and services with our comprehensive analysis of FDA approvals for 2024. This report delves into the trends and key conclusions from a decade of data, highlighting the significant uptick in outsourcing penetration and the robust growth in biotech funding.